Characteristic transcriptional profiles and enriched gene expression at 7q in MF-LCT. (A) Flowchart depicting the overall clinical samples and experimental design of this study. (B) Histopathological features of biopsied specimens from a tumor-stage MF-LCT and MF-NLCT patient. Hematoxylin and eosin staining. Original magnification ×400. Scale bar = 25 μm. (C) Kaplan-Meier survival analysis of OS and PFS from advanced-stage MF patients classified into MF-LCT and MF-NLCT group. *P < .0001, n = 85. (D) Heatmap of 26 MF-LCT and 23 MF-NLCT samples stratified by top 200 DEGs between MF-LCT and MF-NLCT group. (E) Representative enriched molecular pathways in MF-LCT group via GSEA of 49-patient transcriptional profiles (FDR q-value <0.25, Norminal P < .05). (F) GSEA enrichment plot for romidepsin-resistance gene signature, which consists of upregulated genes in romidepsin-resistant versus romidepsin-sensitive CTCL cases from GSE132053. (G) Heatmap of CNV events identified from InferCNV analysis of 49-patient RNA-seq data and chr7 locus marked with red frame. (H) Enriched positional gene sets in MF-LCT group ranked by normalized enrichment score (FDR q-value <0.25, nominal P < .05). Gene sets at regions of chr7 marked with red color.